(MedPage Today) — CHICAGO — Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial showed.
At the 25-mg dose…
Source link : https://www.medpagetoday.com/meetingcoverage/chest/118083
Author :
Publish date : 2025-10-22 17:20:00
Copyright for syndicated content belongs to the linked Source.
